GE HealthCare’s MIM Software has secured FDA clearance for the use of Monte Carlo dosimetry with MIM SurePlan MRT, which is used for automating and standardizing dosimetry in theranostics treatments.

The Monte Carlo method, recognized as a gold standard for dosimetry, delivers precise dose calculations even in tissues of varying densities, such as the lungs.

The integration of Monte Carlo dosimetry via the Dose Planning Method (DPM) into MIM SurePlan MRT enhances the software's ability to deliver personalized dosimetry in real time, a significant improvement over traditional methods that could take hours to process. This advancement could potentially increase patient access to customized radiopharmaceutical therapies, as MIM SurePlan MRT can now operate on existing hospital infrastructure without additional processing units.
Andrew Nelson, CEO of MIM Software, noted that the new capabilities align with the company's mission to expand access to personalized cancer treatments. The software is trusted by healthcare facilities worldwide and is used in many centers designated as radiopharmaceutical therapy Comprehensive Centers of Excellence by the SNMMI.

Theranostics leverage molecular imaging and targeted therapies to provide tailored treatment plans. Dosimetry is essential in this context, helping clinicians predict the radiation dose absorbed by tissues and tumors.

Monte Carlo dosimetry will be featured at upcoming industry conferences, including the Congress of the European Association of Nuclear Medicine and the Radiological Society of North America Annual Meeting.

Molecular Imaging Homepage